NCT05638269 A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
| NCT ID | NCT05638269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhujiang Hospital |
| Condition | Essential Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,000 participants in total. It began in 2022-03-01 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of various critical chronic diseases, compare the similarities and differences of the microbiome signatures linked to different regions and diseases, and further investigate their impacts on microbiota-based diagnostic models.
Eligibility Criteria
Inclusion Criteria: 1. aged 18-75 years; 2. living in the province where the hospital is located in the last three years; 3. with a medical diagnosis of one of the target diseases; 4. willing to provide written informed consent. Exclusion Criteria: 1. female in pregnancy or lactation(unless the subject is pregnant women); 2. with medical diagnoses of other serious illnesses; 3. with a history of bariatric surgery or intestinal resection, except for appendectomy； 4. individual who was treated with drugs in the preceding 1 month, including antibiotics, metformin, statins, acid inhibitor, probiotics, and probiotics; individuals having consumed yogurt more than 3 times in the preceding 1 month; heavy drinkers who have consumed more than 4 taels of liquor or 1000ml of beer; frequent alcohol consumers who have drunk per week in the last month.
Contact & Investigator
Yan He
STUDY CHAIR
Zhujiang Hospital
Frequently Asked Questions
Who can join the NCT05638269 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Essential Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05638269 currently recruiting?
Yes, NCT05638269 is actively recruiting participants. Contact the research team at zjh13049139791@163.com for enrollment information.
Where is the NCT05638269 trial being conducted?
This trial is being conducted at Chaoyang, China, Nanchuan, China, Yongchuan, China, Fuzhou, China and 11 additional locations.
Who is sponsoring the NCT05638269 clinical trial?
NCT05638269 is sponsored by Zhujiang Hospital. The principal investigator is Yan He at Zhujiang Hospital. The trial plans to enroll 12,000 participants.